2. Signaling Pathways
  3. Anti-infection
  4. SARS-CoV

SARS-CoV

SARS coronavirus

SARS-CoV

Related Products

PDF 0.94 MB

SARS-CoV is the coronavirus (CoV) that causes severe acute respiratory syndrome (SARS). CoVs are enveloped viruses with a positive-sense, single-stranded RNA and can cause health-threatening outbreaks by targeting human respiratory system, including not only SARS, but also Middle East respiratory syndrome (MERS) and SARS-CoV-2 (the cause of COVID-19).

CoVs have four main structural proteins: spike(S), membrane (M), envelope (E), and nucleocapsid (N) proteins. An S protein mediates the CoV entry into host cells by attaching to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), followed by fusion between virus and host cell membranes. Genome replication and subgenomic RNA transcription after entry carry on with the participation of many nonstructural proteins such as Mpro (main protease or 3CLpro), PLpro (papain-like protease) and RdRp (RNA-dependent RNA polymerase). Then the structural proteins are translated, assembled into mature virions, and released via vesicles by exocytosis. It is worth mentioning that a protease called TMPRSS2 (transmembrane protease, serine 2) play important roles throughout the whole life of CoVs (such as attachment, assembling and release) by cleaving S protein. All the proteins and subcellular structures participated in the life cycle of CoVs are promising targets for treatment of disease caused by CoVs.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-157778
    MK-7845
    		Inhibitor
    MK-7845 is a reversible covalent SARS-CoV-2 3CL protease inhibitor with an IC50 of 8.7 nM.
    MK-7845
  • HY-144771
    SARS-CoV-2-IN-14
    		Inhibitor 99.02%
    SARS-CoV-2-IN-14 (compound 6) is a potent inhibitor of SARS-CoV-2 with an IC50 of 0.39 μM. SARS-CoV-2-IN-14 is a niclosamide analogue. SARS-CoV-2-IN-14 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally.
    SARS-CoV-2-IN-14
  • HY-153533
    GRL-1720
    		Inhibitor 98.87%
    GRL-1720 is a potent SARS-CoV-2 Mpro inhibitor with an EC50 value of 15 µM. GRL-1720 shows anti-SARS-CoV2 activity.
    GRL-1720
  • HY-125729
    Ivermectin B1b
    		Inhibitor 98.66%
    Ivermectin B1b is the minor component of Ivermectin. Ivermectin, a potent anti-parasitic agent, inhibits the replication of SARS-CoV-2 in cell culture.
    Ivermectin B1b
  • HY-149321
    SARS-CoV-2 nsp14-IN-3
    		Inhibitor
    SARS-CoV-2 nsp14-IN-3 (4975) is an inhibitor of the SARS-CoV-2 Nsp14 N7-Methyltransferase (IC50: 3.5 μM).
    SARS-CoV-2 nsp14-IN-3
  • HY-141841
    SARS-CoV-2-IN-7
    		Inhibitor 98.84%
    SARS-CoV-2-IN-7 inhibits viral replication with a nanomolar IC50 value (844 nM) in SARS-CoV-2-infected Vero E6 cells.
    SARS-CoV-2-IN-7
  • HY-N10871
    Neocryptomerin
    		Inhibitor 99.14%
    Neocryptomerin, a biflavonoid, shows inhibitory activity against U251, MCF-7, HeLa cell. Neocryptomerin has favorable binding affinities in the active pocket of SARS-CoV-2. Neocryptomerin is the leading compound of rational compounds against COVID-19.
    Neocryptomerin
  • HY-N2949
    Bonducellpin D
    		Inhibitor 98.0%
    Bonducellpin D is a furanoditerpenoid lactone isolated from Caesalpinia minax. Bonducellpin D exhibits broad-spectrum inhibition potential against SARS-CoV Mpro and MERS-CoV Mpro, with an Ki of 467.11 and 284.86 nM, respectively. Bonducellpin D also exhibits moderate anti-cancer activity in vitro.
    Bonducellpin D
  • HY-100304
    KW-8232 free base
    		Inhibitor
    KW-8232 free base, an orally active anti-osteoporotic agent, and can reduces the biosynthesis of PGE2.
    KW-8232 free base
  • HY-B0372AS
    Bromhexine-d3 hydrochloride
    		Inhibitor 99.0%
    Bromhexine-d3 (hydrochloride) is deuterium labeled Bromhexine (hydrochloride). Bromhexine hydrochloride is a potent and specific TMPRSS2 protease inhibitor with an IC50 of 0.75 μM. Bromhexine hydrochloride can prevent and manage SARS-CoV-2 infection. Bromhexine hydrochloride is an autophagy agonist. Bromhexine hydrochloride is a mucolytic cough suppressant and has the potential for a range of respiratory conditions.
    Bromhexine-d<sub>3</sub> hydrochloride
  • HY-170524
    TDI-015051
    		Inhibitor
    TDI-015051 is a highly selective, orally active antiviral agent that targets the coronavirus NSP14 guanine-N7 methyltransferase. TDI-015051 binds to substrates in a non-competitive manner and forms a stable ternary complex, precisely blocking the capping and methylation processes of viral mRNA. TDI-015051 potently inhibits a variety of coronaviruses (including SARS-CoV-2 and MERS). By impairing viral replication and translation and inducing a moderate type I interferon-mediated immune response, it significantly reduces pulmonary viral load and exhibits a synergistic effect with Nirmatrelvir (HY-138687). In addition, TDI-015051 does not inhibit non-coronavirus methyltransferases, and the drug-resistant mutations it induces impair viral fitness, demonstrating excellent antiviral properties and safety. TDI-015051 can be used for research on COVID-19 and the replication mechanism of coronaviruses.The IC50 values of TDI-015051 against SARS-CoV-2, α-hCoV-NL63, α-hCoV-229E, β-hCoV-MERS are 0.15 nM, 1.7 nM, 2.6 nM and 3.6 nM, respectively, and the Ka value against SARS-CoV-2 is 0.061 nM.
    TDI-015051
  • HY-139908
    MERS-CoV-IN-1
    		Inhibitor 99.53%
    MERS-CoV-IN-1 exhibits excellent inhibitory activity against coronavirus. MERS-CoV-IN-1 is useful as a pharmaceutical composition for preventing coronavirus-induced diseases (MERS-CoV and SARS) (extracted from patent WO2018174442A1, compound 1).
    MERS-CoV-IN-1
  • HY-156346
    HCoV-OC43-IN-1
    		Inhibitor 99.25%
    HCoV-OC43-IN-1 (Compound IV-16) is a coronavirus HCoV-OC43 inhibitor. HCoV-OC43-IN-1 has antiviral efficacy (EC50: 90 nM). HCoV-OC43-IN-1 inhibits the mRNA level and expression of viral nucleocapsid protein (NP).
    HCoV-OC43-IN-1
  • HY-P990052
    Simaravibart
    		Inhibitor 98.59%
    Simaravibart (MAD-0004J08) is an IgG1κ antibody targeting the SARS-CoV2 spike (S) glycoprotein receptor binding domain.
    Simaravibart
  • HY-N12697A
    Polycarpine hydrochloride
    		Inhibitor 98.05%
    Polycarpine hydrochloride (1a) is a broad-spectrum Mpro inhibitor (IC50 = 30 nM) that can be isolated from the Polycarpa aurata and also serves as an anti-coronaviral agent. Polycarpine hydrochloride possesses antiviral and antifungal activities, with IC50 values of 30.0 nM and 0.12 μM against SARS-CoV-2 Mpro and PEDV Mpro, respectively.
    Polycarpine hydrochloride
  • HY-N12110
    SMU-CX1
    		Inhibitor 99.9%
    SMU-CX1 is a specific TLR3 inhibitor (IC50: 0.11 μM) with IC50 ranging from 0.14-0.33 μM against multiple influenza A virus subtypes. SMU-CX1 inhibits the viral PB2 and NP proteins with an IC50 of 0.43 μM for SARS-CoV-2 activity. SMU-CX1 also inhibits inflammatory factors in host cells, including IFN-β, IP-10, and CCL-5.
    SMU-CX1
  • HY-139165B
    AT-9010 triethylamine
    		Inhibitor
    AT-9010 triethylamine，a triphosphate active metabolite of AT-527，is a potent inhibitor of NiRAN (a function essential for viral replication). AT-9010 triethylamine can inhibit SARS-CoV-2 replication.
    AT-9010 triethylamine
  • HY-N10109A
    Gallinamide A TFA
    		Inhibitor 99.85%
    Gallinamide A TFA is a linearly depositing peptide and a potent inhibitor of cathepsin L (CatL) (IC50: 17.6 pM). Gallinamide A TFA inhibits SARS-CoV-2 infection by inhibiting CatL (EC50: 28 nM). Gallinamide A TFA also inhibits Plasmodium falciparum (IC50: 50 nM).
    Gallinamide A TFA
  • HY-N8306
    Isojacareubin
    		Inhibitor 98.0%
    Isojacareubin can be isolated from Hypericum japonicum. Isojacareubin covalently inhibits SARS-CoV-2 3CLpro. Isojacareubin also has anti-helicobacter activity. Isojacareubin inhibits PKC, and suppresses hepatocellular carcinoma metastasis and induces apoptosis.
    Isojacareubin
  • HY-144772
    SARS-CoV-2-IN-15
    		Inhibitor 99.65%
    SARS-CoV-2-IN-15 (compound 11) is a potent inhibitor of SARS-CoV-2 with an IC50 of 0.49 μM. SARS-CoV-2-IN-15 is a niclosamide analogue. SARS-CoV-2-IN-15 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally.
    SARS-CoV-2-IN-15
Cat. No. Product Name / Synonyms Species Source